Transcutaneous Spinal Cord Stimulation Enhances Cortical Activity and Improves Lower Urinary Tract Symptoms in Stroke Survivors

Abedi A1, Montero Arcila V2, Morales Ojeda L2, Chapman D2, Ponce S2, Rita J2, Gad P3, Edgerton V4, Ginsberg D2, Jann K5, Kreydin E2

Research Type

Clinical

Abstract Category

Neurourology

Abstract 404
Open Discussion ePosters
Scientific Open Discussion Session 5
Wednesday 27th September 2023
12:35 - 12:40 (ePoster Station 5)
Exhibit Hall
Neuromodulation Voiding Dysfunction Imaging Rehabilitation Urgency/Frequency
1. USC Neurorestoration Center, Department of Neurological Surgery, Keck School of Medicine, University of Southern California, 2. University of Southern California, Institute of Urology, Keck School of Medicine, 3. SpineX Inc, Los Angeles, CA, 4. Research Institute, Rancho Los Amigos National Rehabilitation Center, Downey, CA, 5. University of Southern California, USC Stevens Neuroimaging and Informatics Institute, Los Angeles, CA
Presenter
E

Evgeniy Kreydin

Links

Poster

Abstract

Hypothesis / aims of study
Stroke survivors often develop lower urinary tract symptoms (NLUTS), which can be difficult to treat and have a detrimental effect on their quality of life. Studies have shown that the micturition-associated brain activity (MABA) post-stroke relies on the activation of primitive brain regions, such as the cerebellum and periaqueductal gray, with less activation of cortical regions. Transcutaneous Spinal Cord Stimulation (TSCS) is emerging as a novel electrical neuromodulation technique and is gaining increased clinical support due to its neuro-restoration potential. The aim of this study was to assess changes in brain activity using functional magnetic resonance imaging (fMRI) and patient-reported outcome measures (PROM) following twelve weeks of TSCS therapy.
Study design, materials and methods
This prospective study protocol was approved by the Institutional Review Board, and all participants provided informed consent. Twelve patients with newly developed lower urinary tract symptoms (LUTS) following a stroke underwent TSCS for 24 sessions. 
Patients completed a bladder diary and ICIQ-OAB questionnaire and underwent fMRI+ Urodynamic studies (UDS) before and after therapy. Changes in brain activity were assessed by detecting blood oxygen level-dependent (BOLD) signal intensity, recorded during maximum urgency, and measured 10 seconds before detrusor contraction.  Descriptive statistics and paired t-tests were used when the appropriate neuroimaging analysis was done using Statistical Parametric mapping with a p <0.01 and cluster size of 25 voxels.
Results
A total of 12 participants (5 males and 7 females) with a mean age of 52.8 years old (SD± 9.8) completed the study. Following completion of TSCS, patients reported a decreased perception of urge per void (1.83 ± 0.34 vs. 0.92 ± 0.21: p<0.05), a reduction in the number of urge incontinence episodes (6.96 ± 2.12 vs. 4.15 ± 1.58: p <0.05), and an increased number of urge-free voids per 24 hours (0.27 ± 0.09 vs. 2.29 ± 0.91; p<0.05). ICIQ-OAB scores were significantly lower post-stimulation (9.41 vs. 4.08; p=0.001). fMRI detected increased BOLD signal intensity in the cerebellum, cuneus, and multiple frontal areas, including the inferior, medial, and middle frontal gyri, following TSCS.
Interpretation of results
Patients who had completed twelve weeks of TSCS experienced a significant reduction in PROM, such as perceived urge per void, urgency incontinence episodes, and an increase in urge-free voids per 24 hours. Similarly, ICIQ-OAB scores were significantly lower after completing the TSCS protocol. The changes observed in the PROM are consistent with symptom improvement, which could be explained by the changes in cortical regions.
Concluding message
TSCS shows promising results as a potential treatment for LUTD in stroke survivors. Change in cortical activation may be the mechanism by which TSCS improves LUT symptomatology in this patient population.
Disclosures
Funding Funded by Urology Care Foundation Grant awarded to Evgeniy Kreydin Clinical Trial Yes Registration Number NCT05301335. RCT No Subjects Human Ethics Committee IRB #HS-18-00215 at USC/ IRB #246 RRI Helsinki Yes Informed Consent Yes
18/04/2024 09:27:35